Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; anti-PCSK9 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Dallas, Texas.

Filer	Latest Filing Date	Share-Type	Shares	Market Value	Previously owned	Change
Scoggin Management Lp	2023-08-14	Shares	150K	378K	150K	0
Blue Zone Wealth Advisors, Llc	2023-07-24	Shares	30K	75.60K	27.50K	2.50K
Prime Movers Lab Llc	2023-02-14	Shares	0	0	17.60M	-17.60M

NASDAQ:VAXX

Vaxxinity, Inc.

Last Close

0.10

30/08 20:00

Market Cap

43.74M

Beta: -

Volume Today

100

Avg: 171.44K

PE Ratio

−1.33

PFCF: −1.45

Institutional trades

Institutional Ownership

Current holdings institutionals